Tobramycin 3 mg/mL Solution/ Drops
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Aminoglycoside Antibacterial class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Ophthalmic tobramycin is used to treat eye infections. Tobramycin is in a class of medications called antibiotics. It works by killing bacteria that cause infections.
Read the full MedlinePlus article ↗- Tobramycin is an antibiotic, but the form you have determines exactly what it treats. If you're inhaling it through a nebulizer or using the TOBI Podhaler device, it's being used t...
- That on-off cycle is by design. Inhaling tobramycin for 28 days helps knock back the Pseudomonas bacteria in your lungs, and then the 28-day break gives your body a rest and helps...
- Why do I have to take the inhaled form for 28 days and then stop for 28 days?
- Absolutely not — this is really important. The TOBI Podhaler capsules must never be swallowed. The medicine only works when it's inhaled directly into your lungs using the Podhaler...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Tobramycin — tap one for details:
Tobramycin may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $1.108 | $5.54 / 5 ml |
| Medicaid paysCMS SDUD · 12 mo | $1.86 | $9.29 / 5 ml |
| Medicare drug plans payPart D · Q2 2026 | $0.9370 | $4.69 / 5 ml |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Tobramycin 3 mg/mL 24208-0290-05 | Bausch | 1 bottle | $1.108 | AT | Availability likely | — |
| Tobramycin 3 mg/mL 61314-0643-05 | Sandoz | 5 ml | $1.108 | AT | Availability likely | — |
| Tobramycin Ophthalmic Solution 3 mg/mL 62332-0518-05 | Alembic | 1 bottle | $1.108 | AT | Availability likely | — |
| Tobramycin 3 mg/mLthis 70069-0131-01 | Somerset | 1 bottle | $1.108 | AT | Availability likely | — |
| Tobramycin Ophthalmic Solution 3 mg/mL 46708-0518-05 | Alembic | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 50090-2127-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 50090-4190-00 | A-S | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 60760-0583-05 | St. | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 61919-0642-05 | DirectRX | 5 ml | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 62250-0110-01 | Belcher | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 63187-0024-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 63187-0902-02 | Proficient | 1 bottle | — | — | FDA listed | — |
| Tobramycin 3 mg/mL 63187-0973-05 | Proficient | 5 ml | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 66267-0936-05 | NuCare | 5 ml | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 68071-2272-05 | NuCare | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 68083-0374-01 | Gland | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 68788-7252-05 | Preferred | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 70518-1370-00 | REMEDYREPACK | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 71205-0101-05 | Proficient | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 76420-0092-05 | Asclemed | 5 ml | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 76420-0791-05 | Asclemed | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 80425-0341-01 | Advanced | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 85766-0025-05 | Sportpharm | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 85766-0189-05 | Sportpharm | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 86211-0110-01 | JVET | 1 bottle | — | AT | FDA listed | — |
| Tobramycin 3 mg/mL 68788-4149-05 | Preferred | 1 bottle | — | AT | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 70069-0131-01 You're viewing this | 1 BOTTLE in 1 CARTON (70069-131-01) / 5 mL in 1 BOTTLE | 2020-08-11 | Active |
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Tobramycin ophthalmic solution 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.
⛔ Contraindications ▾
CONTRAINDICATIONS Tobramycin ophthalmic solution 0.3% is contraindicated in patients with known hypersensitivity to any of its components.
⚠️ Warnings ▾
WARNINGS FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution 0.3% occurs, discontinue use.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution 0.3%. Postmarketing Experience: Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.
The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson's disease, because of their potential effect on neuromuscular function.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci , including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci , including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata , Acinetobacter calcoaceticus and some Neisseria species.
Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Tobramycin ophthalmic solution USP, 0.3% is supplied as a 5 mL sterile solution, packaged in a 10 mL white LDPE bottle and natural LDPE nozzle and White HDPE cap as follows: 5 mL containing tobramycin 0.3% (3 mg/mL)… NDC 70069- 131 -01. Storage: Store at 2° to 25°C (36° to 77°F). After opening, tobramycin ophthalmic solution 0.3% can be used until the expiration date on the bottle.
For Product Inquiry call +1-800-417-9175 Revised: July, 2024 Manufactured for: Somerset Therapeutics, LLC Somerset, NJ 08873 Made in India Code No.: KR/DRUGS/KTK/28/289/97 1201000 ST-TBR11/P/07
📋 Description ▾
DESCRIPTION Tobramycin ophthalmic solution 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections. Each mL of Tobramycin ophthalmic solution USP, 0.3% contains: Active: tobramycin 0.3% (3 mg). Preservative: benzalkonium chloride 0.01% (0.1 mg).
Inactives: boric acid, sodium sulfate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and water for injection. Tobramycin ophthalmic solution 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg. Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram- negative and gram-positive ophthalmic pathogens.
The chemical structure of tobramycin is: Molecular Weight = 467.52 Molecular Formula: C 18 H 37 N 5 O 9 Chemical Name: 0-{3-amino-3-deoxy-α-D-gluco-pyranosyl (1→4) }-0-{2,6-diamino-2,3,6-trideoxy α-D-ribohexo-pyranosyl-(1→6) }-2 deoxystreptamine. Image